Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B)
Authors:
- Jeffry D. ShearerJSJeffry D. Shearer
- T. Scott ManetzTMT. Scott Manetz
- Robert V. HouseRHRobert V. House
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Botulism and vaccines for its preventionVaccine, 2009
- Antibody Protection against Botulinum Neurotoxin Intoxication in MiceInfection and Immunity, 2009
- Characterization of New Formalin-Detoxified Botulinum Neurotoxin ToxoidsClinical and Vaccine Immunology, 2008
- Genetic Diversity among Botulinum Neurotoxin-Producing Clostridial StrainsJournal of Bacteriology, 2007
- Botulinum Neurotoxin Vaccines: Past, Present, and FutureCritical Reviews in Immunology, 2007
- Human Botulism Immune Globulin for the Treatment of Infant BotulismNew England Journal of Medicine, 2006
- Differentiation of the Gene Clusters Encoding Botulinum Neurotoxin Type A Complexes in Clostridium botulinum Type A, Ab, and A(B) StrainsApplied and Environmental Microbiology, 2004
- Identification of the Major Steps in Botulinum Toxin ActionAnnual Review of Pharmacology and Toxicology, 2004
- Botulinum Toxin as a Biological WeaponJAMA, 2001
- Development of vaccines for prevention of botulismBiochimie, 2000